Table 1.
Demographic Characteristics
| A (N=102) |
B (N=100) |
p value | |
|---|---|---|---|
| Gender | 0.387 | ||
| Female | 82 (80%) | 85 (85%) | |
| Age | 0.546 | ||
| Mean (SD) | 59.5 (11.95) | 58.3 (12.71) | |
| Sleep Scale Group | 0.963 | ||
| Mildly Impaired Sleep Quality | 67 (66%) | 66 (66%) | |
| Mod or Sev Impaired Sleep Quality | 35 (34%) | 34 (34%) | |
| Sleep Scale Score | 0.841 | ||
| Mean (SD) | 6.6 (1.43) | 6.6 (1.69) | |
| Primary Tumor Site | 0.526 | ||
| Breast | 64 (63%) | 66 (67%) | |
| Colon | 9 (9%) | 5 (5%) | |
| Prostate | 3 (3%) | 1 (1%) | |
| Other | 25 (25%) | 27 (27%) | |
| Tumor Status | 0.322 | ||
| Resected with no residual | 64 (64%) | 71 (74%) | |
| Resected with known residual | 17 (17%) | 12 (13%) | |
| Unresected | 19 (19%) | 13 (14%) | |
| Treatment Type | 0.966 | ||
| Radiation therapy | 6 (5.9%) | 6 (6%) | |
| Parenteral chemotherapy | 38 (37%) | 39 (39%) | |
| Oral therapy | 40 (39%) | 40 (40%) | |
| Combined modality | 18 (18%) | 15 (15%) | |
| Concurrent Radiation | 0.926 | ||
| Yes | 23 (23%) | 22 (22%) | |
| Concurrent Cancer Therapy | 0.679 | ||
| Yes | 56 (55%) | 52 (53%) | |
| Planned or Concurrent Hormone | 0.667 | ||
| Yes | 51 (51%) | 53 (54%) |